In the Boardroom
Refine search
Biotechnology
New York-based clinical-stage biotech LB Pharmaceuticals had announced the appointments of Ellen Rose as senior vice president, corporate affairs and Lindsay Beaupre as SVP people and culture. 7 January 2026
Biotechnology
Syncromune, a privately-held US biopharma developing SYNC-T, an in-situ platform combination immunotherapy optimized for solid tumor cancers, has announced the appointment of Stephen Dale as chief medical officer (CMO). 6 January 2026
Biotechnology
Dutch immunology company argenx announced that Karen Massey, current chief operating officer, will transition to chief executive (CEO) and executive director, and Tim Van Hauwermeiren, current chief executive, will transition to non-executive director and chairman. 6 January 2026
Biotechnology
Chris Murphy has been appointed chief executive of privately-held US genetic medicines company, ElevateBio, also joining its board of directors. 5 January 2026
Generics
Paul Burden has been appointed associate vice president and country head of Accord UK, effective immediately. 5 January 2026
Pharmaceutical
Abingworth, a transatlantic life sciences investment firm and part of global investment firm Carlyle, today announced several leadership changes. 5 January 2026
Biotechnology
German drug discovery company Evotec has announced the appointment of Dr Sarah Fakih as executive vice president, head of global communications and investor relations. 2 January 2026
Biotechnology
Charlie Gayer will become BioCryst's new chief executive effective January 1. 30 December 2025
Biotechnology
USA and Europe listed biotech PureTech has appointed Robert Lyne as chief executive (CEO), and as a member of the board of directors, effective immediately. 18 December 2025
Biotechnology
Switzerland-based Topadur Pharma, a biotech company developing innovative therapies for vascular regeneration, has announced the appointment of Matthias Schäfer as chief executive. 17 December 2025
Pharmaceutical
US clinical-stage oncology company NanOlogy has appointed David Arthur as chief executive, as it accelerates development of its large surface area microparticle drug platform and prepares a regulatory filing for a rare pediatric brain cancer program. 17 December 2025
Pharmaceutical
UK based liquid medicines maker Rosemont Pharmaceuticals has appointed an American chief executive (CEO) as the business continues to expand into the USA, Canadian and European pharma market. 16 December 2025
Biotechnology
Swedish rare disease specialist Hansa Biopharma announced a reorganization of its European and International Commercial and Medical Affairs operations. 15 December 2025
Biotechnology
California, USA-based biotech Prolynx, which is developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, has announced the closing of a $70 million Series A financing and the appointment of industry veteran Chris Boulton as chief executive (CEO). 12 December 2025
Pharmaceutical
Danish allergy immunotherapy specialist ALK-Abello has appointed Edward Jordan as new executive vice president (EVP) and head of commercial operations in North America, effective January 5, 2026. 3 December 2025
Biotechnology
Trimtech Therapeutics, a UK biotech developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as chairwoman of its board of directors. 2 December 2025
Biotechnology
Privately-held German biotech Tacalyx has appointed Jean Engela as chief executive (CEO). 2 December 2025
Pharmaceutical
UK-based NRG Therapeutics has announced the expansion of its team with the appointment of Paul Thompson as chief development officer (CDO). 1 December 2025
Biotechnology
Dr Pejvack Motlagh has been appointed as the new chief medical officer of French biopharma Genfit, a French biotech company dedicated to improving the lives of patients with rare and life-threatening liver diseases. 28 November 2025
Biotechnology
Australian biotech Cartherics has appointed Dr Ian Nisbet as chief executive (CEO) as part of a planned leadership transition. Prof Alan Trounson AO will transition to the role of deputy chairman of the board, where he will continue to provide his expertise to support the company’s strategic direction. 28 November 2025
Biotechnology
US AI-native pharma company Formation Bio today announced the appointment of Dr Michael Ehlers as chief scientific officer (CSO) and head of R&D. 22 July 2026
Pharmaceutical
Sanofi has announced changes to its executive committee, as the French pharma major streamlines senior leadership under chief executive Belén Garijo. 22 July 2026
Biotechnology
Germany’s Allogenetics today announced the appointment of Dr Jeroen Rovers as chief medical officer (CMO). 21 July 2026
Biotechnology
Mentari Therapeutics has appointed Greg Divis as chief executive officer (CEO) and a member of its board, as the US biotech company prepares to move its migraine prevention pipeline toward the clinic. 20 July 2026
Biotechnology
US biotech Talawar Therapeutics today announced the appointment of Steve Migausky as chief legal and administrative officer. 20 July 2026
Biotechnology
Canadian genetic medicines company enGene Therapeutics announced changes to its board of directors as it prepares for potential regulatory milestones and commercial readiness for its investigational gene therapy, detalimogene voraplasmid, if approved. 17 July 2026
Biotechnology
USA-based biotech company Prolynx has expanded its senior leadership, appointing Simon Harnest as chief financial officer and Amer Mirza as chief scientific officer, as the Emeryville, California, firm pushes a portfolio of long-acting obesity and metabolic disease candidates toward first-in-human testing. 16 July 2026
Biotechnology
Swedish biologics company Simris Group has appointed former Heidelberg Pharma chief executive Andreas Pahl to lead its German subsidiary, Simris Biologics, as it works to advance its antibody-drug conjugate (ADC) payload platform. 15 July 2026
Biotechnology
The German-listed group behind personalized-genetics firm Novogenia has taken its best-known brand as its corporate name, a move it says unifies identity without changing strategy. 15 July 2026
Biosimilars
Swiss generics and biosimilars company Sandoz has announced a set of senior leadership changes designed to sharpen its operations and dealmaking ahead of what it calls a "golden decade" of branded-drug patent expiries. 15 July 2026
Pharmaceutical
UK headquartered ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights in the respiratory clinical development space, has completed a major corporate repositioning and reorganization. The move marks the next stage of the company's development. 14 July 2026
Biotechnology
UK clinical-stage biotech Elevara Medicines today announced the appointment of Mai-Britt Zocca as chief executive (CEO), effective 1 July 2026. Dr Zocca succeeds founder and CEO Emma Tinsley and will lead the company into its next phase of growth. 14 July 2026
Biotechnology
Boston, USA-based clinical-stage biotech Cue Biopharma has announced the appointment of Dr Dominic Borie as chief medical officer (CMO) and head of R&D. 14 July 2026
Pharmaceutical
US pharma major Pfizer has changed the leadership of its obesity discovery group, with Danna Breen appointed vice president and head of obesity discovery following the departure of longtime scientific leader Kendra Bence. 13 July 2026
Biotechnology
US RNA medicines focused biotech Stoke Therapeutics today announced that Thomas McCauley has been appointed chief scientific officer (CSO). 13 July 2026
Biotechnology
Heidelberg, Germany-based research institute BioMed X and German drug major Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s US R&D headquarters in Ridgefield, Connecticut. 9 July 2026
Pharmaceutical
San Diego, USA-based ARS Pharmaceuticals has announced a chief executive (CEO) succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective July 6, 2026. 9 July 2026
Pharmaceutical
Dutch contract research, development and manufacturing organization (CRDMO) Symeres and Axxam, a provider of biology-driven discovery services, today announced the appointment of Russell Thomas as chief scientific officer to drive a joint collaboration between Symeres and Axxam that combines the unique R&D services offering of both organizations. 8 July 2026
Biotechnology
US precision oncology biotech Stipple Bio has appointed Roland Gendron as chief business officer as it prepares to move lead candidate STP-100 into early clinical studies. 8 July 2026
Pharmaceutical
Florida, USA-based clinical-stage biopharma DemeRx has appointed Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from pre-clinical research through clinical development. 8 July 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze